Literature DB >> 21354172

Role and mechanism of subcellular Ca2+ distribution in the action of two inotropic agents with different toxicity.

Matteo Alemanni1, Marcella Rocchetti, Daniele Re, Antonio Zaza.   

Abstract

Pro-arrhythmic risk strongly limits the therapeutic value of current inotropic interventions. Istaroxime (previously PST2744) is a novel inotropic agent, significantly less pro-arrhythmic than digoxin that, in addition to block Na(+)/K(+) pump, stimulates sarcoplasmic reticulum (SR) Ca(2+) ATPase (SERCA2). Here we compare istaroxime and digoxin effects to further address the role of SR modulation in reducing the toxicity associated with Na(+)/K(+) pump blockade. In murine ventricular myocytes both compounds increased cell twitch (inotropy) in a concentration-dependent fashion. At high concentrations digoxin, but not istaroxime, induced unstimulated contractions, a sign of pro-arrhythmic toxicity. To evaluate the mechanism of this difference, we compared the two drugs at concentrations exerting equal inotropy but different toxicity. At these concentrations: (1) the two drugs equally inhibited the Na(+)/K(+) pump; (2) digoxin induced larger increases in resting Ca(2+) and in diastolic Ca(2+) during pacing; (3) neither drug affected the relationship between RyR-mediated SR Ca(2+) leak and Ca(2+) content; (4) istaroxime, but not digoxin, enhanced SR Ca(2+) reuptake rate. In conclusion, digoxin toxicity was associated to larger accumulation of cytosolic Ca(2+), which did not result from RyR facilitation, but which might ultimately induce it to promote unstimulated Ca(2+) release. The lower toxicity of Na(+)/K(+) pump blockade by istaroxime may thus reflect improved Ca(2+) confinement within the SR, likely to result from concomitant SERCA2 stimulation.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21354172     DOI: 10.1016/j.yjmcc.2011.02.008

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  10 in total

1.  SERCA2a stimulation by istaroxime: a novel mechanism of action with translational implications.

Authors:  Christopher L H Huang
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

2.  Digoxin and adenosine triphosphate enhance the functional properties of tissue-engineered cartilage.

Authors:  Eleftherios A Makris; Brian J Huang; Jerry C Hu; Ye Chen-Izu; Kyriacos A Athanasiou
Journal:  Tissue Eng Part A       Date:  2014-12-04       Impact factor: 3.845

3.  Highly Selective SERCA2a Activators: Preclinical Development of a Congeneric Group of First-in-Class Drug Leads against Heart Failure.

Authors:  Andrea Luraghi; Mara Ferrandi; Paolo Barassi; Martina Arici; Shih-Che Hsu; Eleonora Torre; Carlotta Ronchi; Alessio Romerio; Gwo-Jyh Chang; Patrizia Ferrari; Giuseppe Bianchi; Antonio Zaza; Marcella Rocchetti; Francesco Peri
Journal:  J Med Chem       Date:  2022-05-17       Impact factor: 8.039

4.  Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition.

Authors:  Mara Ferrandi; Paolo Barassi; Francesco Tadini-Buoninsegni; Gianluca Bartolommei; Isabella Molinari; Maria Grazia Tripodi; Cristina Reina; Maria Rosa Moncelli; Giuseppe Bianchi; Patrizia Ferrari
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

Review 5.  Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials.

Authors:  Tariq Ahmad; P Elliott Miller; Megan McCullough; Nihar R Desai; Ralph Riello; Mitchell Psotka; Michael Böhm; Larry A Allen; John R Teerlink; Giuseppe M C Rosano; Joann Lindenfeld
Journal:  Eur J Heart Fail       Date:  2019-08-13       Impact factor: 15.534

6.  Stress-induced premature senescence is associated with a prolonged QT interval and recapitulates features of cardiac aging.

Authors:  Edoardo Lazzarini; Alessandra Maria Lodrini; Martina Arici; Sara Bolis; Sara Vagni; Stefano Panella; Azucena Rendon-Angel; Melissa Saibene; Alessia Metallo; Tiziano Torre; Giuseppe Vassalli; Pietro Ameri; Claudia Altomare; Marcella Rocchetti; Lucio Barile
Journal:  Theranostics       Date:  2022-07-04       Impact factor: 11.600

7.  Istaroxime: A rising star in acute heart failure.

Authors:  Suruchi Aditya; Aditya Rattan
Journal:  J Pharmacol Pharmacother       Date:  2012-10

8.  Functional characterization and anti-cancer action of the clinical phase II cardiac Na+/K+ ATPase inhibitor istaroxime: in vitro and in vivo properties and cross talk with the membrane androgen receptor.

Authors:  Konstantinos Alevizopoulos; Konstantinos Dimas; Natalia Papadopoulou; Eva-Maria Schmidt; Anna Tsapara; Saad Alkahtani; Sabina Honisch; Kyriakos C Prousis; Saud Alarifi; Theodora Calogeropoulou; Florian Lang; Christos Stournaras
Journal:  Oncotarget       Date:  2016-04-26

9.  Istaroxime, a potential anticancer drug in prostate cancer, exerts beneficial functional effects in healthy and diseased human myocardium.

Authors:  Markus Wallner; Mounir Khafaga; Ewald Kolesnik; Aris Vafiadis; Gerold Schwantzer; Deborah M Eaton; Pero Curcic; Martin Köstenberger; Igor Knez; Peter P Rainer; Martin Pichler; Burkert Pieske; Dirk Von Lewinski
Journal:  Oncotarget       Date:  2017-07-25

10.  SERCA2a stimulation by istaroxime improves intracellular Ca2+ handling and diastolic dysfunction in a model of diabetic cardiomyopathy.

Authors:  Eleonora Torre; Martina Arici; Alessandra Maria Lodrini; Mara Ferrandi; Paolo Barassi; Shih-Che Hsu; Gwo-Jyh Chang; Elisabetta Boz; Emanuela Sala; Sara Vagni; Claudia Altomare; Gaspare Mostacciuolo; Claudio Bussadori; Patrizia Ferrari; Giuseppe Bianchi; Marcella Rocchetti
Journal:  Cardiovasc Res       Date:  2022-03-16       Impact factor: 10.787

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.